Ignite Creation Date:
2024-05-06 @ 1:30 AM
Last Modification Date:
2024-10-26 @ 11:05 AM
Study NCT ID:
NCT01827059
Status:
UNKNOWN
Last Update Posted:
2017-08-16
First Post:
2013-04-05
Brief Title:
Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE
Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Organization:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Study Overview
Official Title:
A Randomized Placebo Controlled Trial to Analyze Changes in Pulmonary Arterial Pressures at Peak Exercise in Congenital Heart Disease Patients With Exercise-induced Pulmonary Arterial Hypertension Before and After Treatment With Bosentan Compared to Placebo
Status:
UNKNOWN
Status Verified Date:
2017-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BICYCLE
Brief Summary:
SUMMARY Rationale Pulmonary arterial hypertension PAH can be a rapidly progressive disorder and is associated with a high mortality rate despite medical intervention With the availability of effective therapy early disease detection is an important strategic objective to improve treatment outcomes Resting echocardiography is currently the recommended screening modality for high-risk population groups However it is clear that abnormalities in resting hemodynamics and symptoms are late sequelae of the pathobiological processes that begin in the distal pulmonary arteries Exercise stress may unmask early pulmonary vascular dysfunction however the definition clinical significance and natural history of exercise PAH remain undefined However based on clinical experience and literature the prevalence is estimated at 20Treatment with endothelin receptor blockers has shown a beneficial influence on the clinical performance in patients with exercise induced PAH due to systemic sclerosis and primary pulmonary hypertension Whether endothelin receptor blockers decrease pulmonary pressures and improve clinical outcome in patients with exercise induced pulmonary arterial hypertension due to congenital heart disease is unknown
Objective Identify congenital heart disease patients with exercise-induced pulmonary arterial hypertension Analyze changes in pulmonary arterial pressures at peak exercise in patients with exercise induced pulmonary arterial hypertension before and after treatment with bosentan compared to placebo
Study design Randomized placebo controlled trial with a study period of 26 weeks
Study population Adult congenital heart disease patients with exercise induced pulmonary arterial hypertension n40 from the Academic Medical Centre Amsterdam
Intervention After randomization one group n20 receives a 125 mg tablet of Bosentan twice daily for 6 months The other group n20 receives placebo for 6 months
Main study parametersendpoints To determine wether bosentan endothelin receptor inhibitor decreases mean pulmonary arterial pressure at peak exercise in adult congenital heart disease patients with exercise induced pulmonary arterial hypertension Furthermore the change in cardiopulmonary exercise capacity and right ventricular function will be investigated
Nature and extent of the burden and risks associated with participation benefit and group relatedness All investigations blood analysis excepted are non-invasive and free of risk The burden for the patients mainly consists of the time that is consumed by the investigations namely history taking physical examination 15 min Quality-of-Life- score 15 min laboratory tests electrolytes creatinine urea albumin and neurohormones troponin T 12 lead electrocardiogram 10 min exercise echocardiography 30 min cardiovascular exercise testing 30 min
The trial medication has a potential risk of liver damage which will be monitored regularly by laboratory testing of liver transaminases
Objective Identify congenital heart disease patients with exercise-induced pulmonary arterial hypertension Analyze changes in pulmonary arterial pressures at peak exercise in patients with exercise induced pulmonary arterial hypertension before and after treatment with bosentan compared to placebo
Study design Randomized placebo controlled trial with a study period of 26 weeks
Study population Adult congenital heart disease patients with exercise induced pulmonary arterial hypertension n40 from the Academic Medical Centre Amsterdam
Intervention After randomization one group n20 receives a 125 mg tablet of Bosentan twice daily for 6 months The other group n20 receives placebo for 6 months
Main study parametersendpoints To determine wether bosentan endothelin receptor inhibitor decreases mean pulmonary arterial pressure at peak exercise in adult congenital heart disease patients with exercise induced pulmonary arterial hypertension Furthermore the change in cardiopulmonary exercise capacity and right ventricular function will be investigated
Nature and extent of the burden and risks associated with participation benefit and group relatedness All investigations blood analysis excepted are non-invasive and free of risk The burden for the patients mainly consists of the time that is consumed by the investigations namely history taking physical examination 15 min Quality-of-Life- score 15 min laboratory tests electrolytes creatinine urea albumin and neurohormones troponin T 12 lead electrocardiogram 10 min exercise echocardiography 30 min cardiovascular exercise testing 30 min
The trial medication has a potential risk of liver damage which will be monitored regularly by laboratory testing of liver transaminases
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None